Abstract
Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs.
Keywords: COVID-19 convalescent plasma; Efficacy; IgG subclasses; Neutralizing antibodies; Pathogen inactivation; Pathogen reduction technologies.
All Keywords
【저자키워드】 Efficacy, Neutralizing antibodies, IgG subclasses, COVID-19 convalescent plasma, Pathogen inactivation, Pathogen reduction technologies., 【초록키워드】 COVID-19, convalescent plasma, neutralizing antibody, IgG, COVID19, Infection, convalescent, NAb, Evidence, Concentration, detrimental, reduction, while, regulatory authority, residual risk, lack, 【제목키워드】 COVID-19, convalescent plasma, Impact,
【저자키워드】 Efficacy, Neutralizing antibodies, IgG subclasses, COVID-19 convalescent plasma, Pathogen inactivation, Pathogen reduction technologies., 【초록키워드】 COVID-19, convalescent plasma, neutralizing antibody, IgG, COVID19, Infection, convalescent, NAb, Evidence, Concentration, detrimental, reduction, while, regulatory authority, residual risk, lack, 【제목키워드】 COVID-19, convalescent plasma, Impact,
{{{ 추상적인 }}}
COVID19 회복기 혈장과 관련된 수혈 전파 감염의 잔류 위험을 최소화하기 위해 많은 규제 당국에서 병원체 감소 기술(PRT)을 권장했습니다. 안전성과 비용 효율성에 대한 영향이 현재 잘 입증되어 있지만 PRT가 중화 항체(nAb)의 농도 및/또는 기능을 변경하여 회복기 혈장의 효능에 영향을 미칠 수 있다는 이론적 우려가 있습니다. 우리는 여기에서 nAbs에 대한 PRT의 유의미한 해로운 영향의 부족을 뒷받침하는 증거를 검토합니다.
{{ 키워드: }} 코로나19 회복기 혈장; 효능; IgG 서브클래스; 중화 항체; 병원체 불활성화; 병원체 감소 기술.